Malnutrition and tuberculosis: the gap between basic research and clinical trials.

J Infect Dev Ctries

Laboratory of Integrative Inmunology, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico.

Published: March 2021

AI Article Synopsis

  • Mycobacterium tuberculosis (M.tb) causes tuberculosis (TB), a major global health issue linked to risk factors like malnutrition, HIV, and diabetes.
  • Research shows a connection between micronutrients and immune response to M.tb, but clinical trials yield mixed results, highlighting a gap in understanding.
  • There's a need for more studies that bridge laboratory findings and clinical applications to develop effective treatments for TB patients.

Article Abstract

Mycobacterium tuberculosis (M.tb) is the causative agent of tuberculosis (TB), an infectious disease that leads to numerous deaths worldwide. Malnutrition, smoking, alcohol abuse, Human Immunodeficiency Virus infection, and diabetes are some of the most important risk factors associated with TB development. At present, it is necessary to conduct studies on risk factors to establish new effective strategies and combat this disease. Malnutrition has been established as a risk factor since several years ago; although there is in vitro experimental evidence that reveals the importance of micronutrients in activating the immune response against M.tb, evidence from clinical trials is controversial. Currently, nutritional assessment is recommended in all TB patients upon diagnosis. However, there is insufficient evidence to indicate micronutrient supplementation as adjuvant therapy or prophylactic to prevent micronutrient depletion. Strengthening the interaction between basic and clinical research is necessary to carry out studies that will help establish adjuvant therapies to improve outcomes in TB patients. In this review, we discuss the experimental evidence, provided by basic research, regarding micronutrients in the TB field. However, when these studies are applied to clinical trials, the data are inconsistent, indicating that still missing mechanisms are necessary to propose alternatives to the treatment of TB patients.

Download full-text PDF

Source
http://dx.doi.org/10.3855/jidc.12821DOI Listing

Publication Analysis

Top Keywords

clinical trials
12
basic clinical
8
risk factors
8
experimental evidence
8
malnutrition tuberculosis
4
tuberculosis gap
4
gap basic
4
clinical
4
trials mycobacterium
4
mycobacterium tuberculosis
4

Similar Publications

Automated Classification of Cardiac Arrhythmia using Short-Duration ECG Signals and Machine Learning.

Biomed Phys Eng Express

January 2025

Electronics and Communication Engineering, Rajiv Gandhi University, Rono Hills, Doimukh, ITANAGAR, Itanagar, Arunachal Pradesh, 791112, INDIA.

Accurate detection of cardiac arrhythmias is crucial for preventing premature deaths. The current study employs a dual-stage Discrete Wavelet Transform (DWT) and a median filter to eliminate noise from ECG signals. Subsequently, ECG signals are segmented, and QRS regions are extracted for further preprocessing.

View Article and Find Full Text PDF

Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability.

Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010-April 15, 2019.

View Article and Find Full Text PDF

Background: Young patients aged 16 to 25 years with type 1 diabetes (T1D) often encounter challenges related to deteriorating disease control and accelerated complications. Mobile apps have shown promise in enhancing self-care among youth with diabetes. However, inconsistent findings suggest that further evidence is necessary to confirm the effectiveness of app-based interventions.

View Article and Find Full Text PDF

Background: Physicians worldwide face the challenging task of improving patient satisfaction by reducing pain in injured patients. Currently, available therapeutic approaches provide only short-term relief of symptoms without addressing long-term satisfaction. This has led to exploring regenerative treatment options that can deliver better outcomes.

View Article and Find Full Text PDF

Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!